Infectious oesophagitis (immunocompromised)
Oesophageal · Gastroenterology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Oesophageal infection (Candida, herpes simplex or CMV) in immunocompromised patients (HIV, chemotherapy, transplant, steroids) causing odynophagia, dysphagia and reduced intake.
Red flags
- Inability to swallow secretions/fluids
- Severe dehydration/malnutrition
- Haematemesis (deep ulceration)
- Failure to respond to empirical therapy
Assessment
Differential diagnosis
- Pill oesophagitis
- Reflux oesophagitis
- Eosinophilic oesophagitis
- Oesophageal malignancy
- Caustic injury
Investigations
- Assess hydration and nutritional state
- HIV test/CD4 count and immune status review
- Upper GI endoscopy with brushings/biopsy (white plaques = Candida; ulcers = HSV/CMV)
- FBC, U&E
Management
- Assess ability to swallow and hydration; give IV fluids if needed
- Empirical antifungal for likely candidal oesophagitis (most common)
- Endoscopy with biopsy if no response or diagnosis unclear
- Targeted antiviral for HSV (aciclovir) or CMV (ganciclovir) if confirmed
- Optimise immune status and review causative drugs
- Analgesia for odynophagia
Drugs & doses
Fluconazole (candidal oesophagitis)
Aciclovir (HSV oesophagitis)
Ganciclovir/valganciclovir (CMV oesophagitis)
IV fluids and analgesia
Disposition
Discharge if tolerating oral intake; admit if unable to swallow or dehydrated.
Complications & pitfalls
- Dehydration and malnutrition
- Bleeding or perforation from deep ulcers
- Stricture
- Dissemination of infection
Exam pearls
- Empirical fluconazole is reasonable first-line as Candida is most common
- Linear ulcers favour HSV/CMV over candidal plaques
- A response to antifungals supports the diagnosis
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.